Exploratory Metabolomics Study of Exhaled Breath in Pulmonary Embolism
Key facts
- Who runs it
- University Hospital, Strasbourg, France
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- People taking part
- 1 person enrolled
- Started
- 1 Dec 2021
- Ended
- 15 Jan 2024
- Type of study
- Observational, 2 groups
- Treatments tested
- Pulmonary embolism diagnosis by nuclear medicine imaging
- Record updated
- 29 August 2024
- Why it stopped
- recruitment difficulties
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Male or female, at least 18 years old
- Patients with clinical suspected pulmonary embolism
- Patient willing and able to provide informed consent
Who cannot take part
- Diagnosis of pulmonary embolism established prior to inclusion in the study
- Contraindications to pulmonary ventilator-perfusion tomoscintigraphy
- All types of thrombolytic or anticoagulant treatment
- Massive pulmonary embolism (systolic pressure < 90 mm Hg)
- Pregnancy
- Breastfeeding
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Pulmonary embolism is a frequent and recurrent pathology, especially in the elderly. It is often preventable, with high mortality and morbidity, making it a major public health issue. The clinical presentation of pulmonary embolism is non-specific and very highly variable, ranging from asymptomatic thrombus diagnosed incidentally to sudden death. The current diagnosis of pulmonary embolism is based on several diagnostic techniques, mainly non-invasive, which should be used sequentially.
Read full original descriptionShow less
We propose to sample the volatile organic compounds using a device that allows them to be trapped on polymer cartridges. Sampling will be performed under monitoring of respiratory pressure and a capnograph to collect alveolar and upper respiratory tract air separately without contamination of the oral cavity or sinuses.
This exploratory metabolic analysis will be non-targeted (analysis of all molecules detectable without a priori).
The main objective of the study is to identify specific metabolic profiles to predict the results of ventilation-perfusion pulmonary tomoscintigraphy in subjects undergoing this examination for suspected acute pulmonary embolism.
Secondary purposes :
* To identify metabolic profiles to be used to predict, in combination with clinical probability scores, the results of ventilation-perfusion pulmonary tomoscintigraphy in subjects undergoing this examination for suspected acute pulmonary embolism.; * To correlate metabolic profiles with the topography of embolized lung territories
The 2 groups in the trial
- Presence of pulmonary embolism
≥ 1 noninfused and normoventilated segment(s) by pulmonary tomoscintigraphy
Treatment: Pulmonary embolism diagnosis by nuclear medicine imaging
- No pulmonary embolism
Pulmonary perfusion without anomaly (segmental or sub-segmental) by pulmonary tomoscintigraphy
Treatment: Pulmonary embolism diagnosis by nuclear medicine imaging
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 29 August 2024